SARAPACK
DEAD

Add to watchlist:

No watchlists yet
View on USPTO

SARAPACK Trademark

Serial Number: 87324025

SARAPACK is a trademark filed by ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED on February 3, 2017. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (253 trademarks)

CLONSHAUGH BUSINESS & TECHNOLOGY PARK
COOLOCK, DUBLIN 17 , IE

Entity Type: 77

Trademark Details

Filing Date

February 3, 2017

Registration Date

Not Registered

Published for Opposition

May 16, 2017

Goods & Services

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure diseases and disorders; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; Pharmaceuticals, namely, neuroprotective agents; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical preparations for skin care used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatories, anti-infectives, anti-glaucoma eye drops and decongestant formulations; sterile ointments for medical use; ocular wetting solutions, artificial tears and formulations pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, skin rejuvenators, rehydrating creams, and lotions for the face and body

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Aug 17, 2020 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Aug 17, 2020 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 11, 2020 EXRA
SOU EXTENSION 5 GRANTED
Jan 10, 2020 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jan 10, 2020 AITU
SOU EXTENSION 5 FILED
Jan 6, 2020 EXT5
SOU TEAS EXTENSION RECEIVED
Jan 6, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 18, 2019 EXRA
SOU EXTENSION 4 GRANTED
Jun 14, 2019 EX4G
SOU EXTENSION 4 FILED
Jun 14, 2019 EXT4
SOU TEAS EXTENSION RECEIVED
Jun 14, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 11, 2018 EXRA
SOU EXTENSION 3 GRANTED
Dec 7, 2018 EX3G
SOU EXTENSION 3 FILED
Dec 7, 2018 EXT3
SOU TEAS EXTENSION RECEIVED
Dec 7, 2018 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 3, 2018 EXRA
SOU EXTENSION 2 GRANTED
Jun 29, 2018 EX2G
SOU EXTENSION 2 FILED
Jun 29, 2018 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 29, 2018 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 12, 2017 EXRA
SOU EXTENSION 1 GRANTED
Dec 8, 2017 EX1G
SOU EXTENSION 1 FILED
Dec 8, 2017 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 8, 2017 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 11, 2017 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 16, 2017 NPUB
PUBLISHED FOR OPPOSITION
May 16, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 26, 2017 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Apr 11, 2017 PREV
ASSIGNED TO LIE
Apr 10, 2017 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 15, 2017 CNSA
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 13, 2017 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 13, 2017 GNSL
SUSPENSION LETTER WRITTEN
Mar 13, 2017 CNSL
ASSIGNED TO EXAMINER
Mar 13, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 8, 2017 NWOS
NEW APPLICATION ENTERED
Feb 7, 2017 NWAP